- Home
- FE vs CRNX Comparison
FE vs CRNX Comparison
Compare FE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$47.20
Company Overview
Basic Information| Metric | FE | CRNX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9B | 4.1B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FE | CRNX |
|---|---|---|
| Price | $44.96 | $47.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | $48.33 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 4.3M | 992.2K |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ 48.81 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $14,283,000,000.00 | $1,535,000.00 |
| Revenue This Year | $10.54 | $425.41 |
| Revenue Next Year | $3.60 | $943.30 |
| P/E Ratio | $19.44 | ★ N/A |
| Revenue Growth | 7.74 | ★ 47.74 |
| 52 Week Low | $37.58 | $24.10 |
| 52 Week High | $48.20 | $54.18 |
Technical Indicators
Market Signals| Indicator | FE | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 52.35 |
| Support Level | $43.91 | $43.04 |
| Resistance Level | $44.81 | $49.61 |
| Average True Range (ATR) | 0.52 | 1.94 |
| MACD | 0.08 | -0.24 |
| Stochastic Oscillator | 68.83 | 55.10 |
Price Performance
Historical Comparison FE
CRNX
About FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.